Mammoth Biosciences
mammoth.bioOperator of a biotechnology company intended to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics.
LBX PPS
1Y return
$4.67
↓ 65.3% 1Y
Implied Valuation
$482.6M
-65.3% premium
Last Round
Apr 2024
$13.45
Series D · $1.4B
Price per share
12M · USD
Loading chart...
Funding history
$M raised · $B post-money
Loading chart...
Explore related companies
More company profiles from the LBX Pro directory.